Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDS.

Barreau S, Green AS, Dussiau C, Alary AS, Raimbault A, Mathis S, Willems L, Bouscary D, Kosmider O, Bardet V, Fontenay M, Chapuis N.

Cytometry B Clin Cytom. 2019 Sep 9. doi: 10.1002/cyto.b.21843. [Epub ahead of print]

PMID:
31498561
2.

Paraneoplastic hyperleukocytosis mimicking hematologic malignancy revealing a localized lung cancer.

Marouf A, Chapuis N, Alary AS, Burroni B, Kosmider O, Alifano M, Bouscary D.

Ann Thorac Surg. 2019 Aug 10. pii: S0003-4975(19)31164-6. doi: 10.1016/j.athoracsur.2019.06.064. [Epub ahead of print]

PMID:
31408646
3.

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M.

Sci Transl Med. 2019 Jul 10;11(500). pii: eaav5467. doi: 10.1126/scitranslmed.aav5467.

PMID:
31292266
4.

Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.

Mondesir J, Alary AS, Sibon D, Willems L, Deau B, Suarez F, Hermine O, Fontenay M, Bouscary D, Kosmider O, Tamburini J.

Br J Haematol. 2019 Oct;187(1):65-72. doi: 10.1111/bjh.16045. Epub 2019 Jun 18.

PMID:
31215036
5.

The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.

Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford-Weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V.

Cytometry B Clin Cytom. 2019 May;96(3):215-222. doi: 10.1002/cyto.b.21781. Epub 2019 Apr 9.

PMID:
30963682
6.

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.

Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM.

Haematologica. 2019 Oct;104(10):2017-2027. doi: 10.3324/haematol.2018.205385. Epub 2019 Mar 28.

7.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E.

Leukemia. 2019 Oct;33(10):2466-2480. doi: 10.1038/s41375-019-0447-3. Epub 2019 Mar 20.

PMID:
30894665
8.

Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin.

Sibon D, Coman T, Rossignol J, Lamarque M, Kosmider O, Bayard E, Fouquet G, Rignault R, Topçu S, Bonneau P, Bernex F, Dussiot M, Deroy K, Laurent L, Callebert J, Launay JM, Georgin-Lavialle S, Courtois G, Maroteaux L, Vaillancourt C, Fontenay M, Hermine O, Côté F.

Cell Rep. 2019 Mar 19;26(12):3246-3256.e4. doi: 10.1016/j.celrep.2019.02.071.

9.

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Wassef M, Luscan A, Aflaki S, Zielinski D, Jansen PWTC, Baymaz HI, Battistella A, Kersouani C, Servant N, Wallace MR, Romero P, Kosmider O, Just PA, Hivelin M, Jacques S, Vincent-Salomon A, Vermeulen M, Vidaud M, Pasmant E, Margueron R.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.

10.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

11.

T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2019 Mar;104(3):e117-e120. doi: 10.3324/haematol.2018.205542. Epub 2018 Dec 20. No abstract available.

12.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

13.

Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia.

Bories PN, Nakib S, Cynober L, Alary AS, Coude MM, Chevillon F, Tamburini J, Birsen R, Kosmider O, Bouscary D.

Clin Chem Lab Med. 2019 Mar 26;57(4):e57-e59. doi: 10.1515/cclm-2018-0427. No abstract available.

PMID:
30267623
14.

Development of digital PCR molecular tests for clinical practice: principles, practical implementation and recommendations.

Denis JA, Nectoux J, Lamy PJ, Rouillac Le Sciellour C, Guermouche H, Alary AS, Kosmider O, Sarafan-Vasseur N, Jovelet C, Busser B, Nizard P, Taly V, Fina F.

Ann Biol Clin (Paris). 2018 Oct 1;76(5):505-523. doi: 10.1684/abc.2018.1372. Review.

PMID:
30226193
15.

CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.

Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary AS, Burroni B, Kosmider O, Fontenay M, Béné MC, Durrieu F, Bettelheim P, Bardet V.

Br J Haematol. 2019 Feb;184(4):625-633. doi: 10.1111/bjh.15584. Epub 2018 Sep 10.

PMID:
30198568
16.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.

17.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.

EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.

18.

Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes.

Meunier M, Dussiau C, Mauz N, Alary AS, Lefebvre C, Szymanski G, Pezet M, Blanquet F, Kosmider O, Park S.

Oncotarget. 2018 Feb 20;9(19):14993-15000. doi: 10.18632/oncotarget.24538. eCollection 2018 Mar 13.

19.

Knockdown of Human AMPK Using the CRISPR/Cas9 Genome-Editing System.

Grenier A, Sujobert P, Olivier S, Guermouche H, Mondésir J, Kosmider O, Viollet B, Tamburini J.

Methods Mol Biol. 2018;1732:171-194. doi: 10.1007/978-1-4939-7598-3_11.

PMID:
29480475
20.

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, Rousseau A, Fenaux P, Chevret S, Chapuis N, Boeva V, Fridman WH, Fontenay M, Kosmider O.

Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3. No abstract available.

PMID:
28972593
21.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
22.

Dyserythropoiesis of myelodysplastic syndromes.

Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M.

Curr Opin Hematol. 2017 May;24(3):191-197. doi: 10.1097/MOH.0000000000000325. Review.

PMID:
28072603
23.

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.

Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E.

Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23.

24.

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M.

Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.

PMID:
27856460
25.

Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.

Saillard C, Guermouche H, Derrieux C, Bruneau J, Frenzel L, Couronne L, Asnafi V, Macintyre E, Trinquand A, Lhermitte L, Molina T, Suarez F, Lemonnier F, Kosmider O, Delarue R, Hermine O, Cheminant M.

Hematol Oncol. 2017 Dec;35(4):864-868. doi: 10.1002/hon.2319. Epub 2016 Jun 29.

PMID:
27353473
26.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. No abstract available.

27.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

28.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, Chevret S, Lejeune J, Raimbault A, Stamatoullas A, Rose C, Beyne-Rauzy O, Delaunay J, Solary E, Fenaux P, Dreyfus F, Preudhomme C, Kosmider O, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.

29.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.

Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

30.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

31.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E.

Blood Cancer J. 2015 Feb 13;5:e280. doi: 10.1038/bcj.2015.9. No abstract available.

32.

Mutations of ETNK1 in aCML and CMML.

Kosmider O.

Blood. 2015 Jan 15;125(3):422-3. doi: 10.1182/blood-2014-11-609057. No abstract available.

PMID:
25593331
33.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.

Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E.

Blood Cancer J. 2015 Jan 2;5:e270. doi: 10.1038/bcj.2014.90. Erratum in: Blood Cancer J. 2015;5:e280. Blood Cancer J. 2015;5:e280.

34.

Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.

Cheminant M, Bruneau J, Kosmider O, Lefrere F, Delarue R, Gaulard P, Radford I, Derrieux C, Hermine O, Lemonnier F.

Br J Haematol. 2015 Mar;168(6):913-6. doi: 10.1111/bjh.13170. Epub 2014 Oct 14. No abstract available.

PMID:
25312805
35.

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Solary E, Tefferi A, Patnaik MM.

Am J Hematol. 2014 Dec;89(12):1111-5. doi: 10.1002/ajh.23846. Epub 2014 Sep 26.

36.

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E.

Leukemia. 2014 Nov;28(11):2206-12. doi: 10.1038/leu.2014.125. Epub 2014 Apr 3.

PMID:
24695057
37.

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

Itzykson R, Kosmider O, Fenaux P.

Best Pract Res Clin Haematol. 2013 Dec;26(4):355-64. doi: 10.1016/j.beha.2014.01.001. Epub 2014 Jan 13. Review.

PMID:
24507812
38.

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG, Damm F, Popova T, Marais R, Fontenay M, Roman-Roman S, Bernard OA, Stern MH.

Leukemia. 2014 Jun;28(6):1355-7. doi: 10.1038/leu.2014.28. Epub 2014 Jan 17. No abstract available.

PMID:
24434863
39.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenay M, Gozzini A, Bosi A, Santini V.

Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6.

40.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, Itzykson R, Sanada M, Shiraishi Y, Gelsi-Boyer V, Renneville A, Miyano S, Mori H, Shih LY, Park S, Dreyfus F, Guerci-Bresler A, Solary E, Rose C, Cheze S, Prébet T, Vey N, Legentil M, Duffourd Y, de Botton S, Preudhomme C, Birnbaum D, Bernard OA, Ogawa S, Fontenay M, Kosmider O.

Blood. 2013 Oct 31;122(18):3169-77. doi: 10.1182/blood-2012-11-469619. Epub 2013 Sep 18.

PMID:
24047651
41.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

42.

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Kosmider O, Itzykson R, Chesnais V, Lasho T, Laborde R, Knudson R, Gauthier A, Merlevede J, Ades L, Morabito M, Fontenay M, Tefferi A, Droin N, Solary E.

Leukemia. 2013 Sep;27(9):1946-9. doi: 10.1038/leu.2013.182. Epub 2013 Jun 18. No abstract available.

PMID:
23774674
43.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S, Dreyfus F, Lacombe C, Béné MC, Kosmider O, Fontenay M, Bardet V.

Leukemia. 2013 Oct;27(10):1981-7. doi: 10.1038/leu.2013.178. Epub 2013 Jun 14.

PMID:
23765225
44.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E.

J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.

PMID:
23690417
45.

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.

D'allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, Floquet C, Dubreuil P, Lacombe C, Fontenay M, Mayeux P, Kosmider O.

PLoS One. 2013 Apr 23;8(4):e60961. doi: 10.1371/journal.pone.0060961. Print 2013.

46.

Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.

Ettou S, Humbrecht C, Benet B, Billot K, d'Allard D, Mariot V, Goodhardt M, Kosmider O, Mayeux P, Solary E, Fontenay M.

Mol Cancer Res. 2013 Jul;11(7):724-35. doi: 10.1158/1541-7786.MCR-12-0607. Epub 2013 Apr 19.

47.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, Gelsi-Boyer V, de Botton S, Vey N, Preudhomme C, Clavert A, Delabesse E, Park S, Birnbaum D, Fontenay M, Bernard OA, Solary E.

Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5. No abstract available.

PMID:
23443343
48.

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C, Ades L, Santini V, Park S, Toma A, Fenaux P, Dreyfus F, Fontenay M, Kosmider O.

Leukemia. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26. No abstract available.

PMID:
23434730
49.

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Chesnais V, Kosmider O, Damm F, Itzykson R, Bernard OA, Solary E, Fontenay M.

Oncotarget. 2012 Nov;3(11):1284-93. Review.

50.

Clonal architecture of chronic myelomonocytic leukemias.

Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Adès L, Fenaux P, Platzbecker U, Gagey O, Rameau P, Meurice G, Oréar C, Delhommeau F, Bernard OA, Fontenay M, Vainchenker W, Droin N, Solary E.

Blood. 2013 Mar 21;121(12):2186-98. doi: 10.1182/blood-2012-06-440347. Epub 2013 Jan 14.

PMID:
23319568

Supplemental Content

Loading ...
Support Center